Home
>
US Stocks
>
Kura Oncology Inc
Kura Oncology Inc
KURA

Kura Oncology Inc

$18.044.8%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
18.65
Today Low/High
17.98 / 18.7
52 Week Low/High
$15.5 / $43
Market Cap
$1.07B

Company Details

Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets; however, no molecular mechanism of action had been determined that could explain its clinical activity across a range of solid tumor and hematologic indications. Leveraging advances in next generation sequencing as well as emerging information about cancer genetics and tumor biology, the Company is seeking to identify those patients most likely to benefit from tipifarnib. In addition to Breakthrough Therapy Designation, tipifarnib has been granted Fast Track designation by the FDA for the treatment of patients with HRAS mutant HNSCC. In addition to HNSCC, tipifarnib has demonstrated encouraging clinical activity in a number of additional genetically defined tumor types. Kura has received multiple issued patents for tipifarnib, providing patent exclusivity in the U.S. and foreign countries. About Kura Oncology
Organisation
Kura Oncology Inc
Headquaters
San Diego, California, US
Employees
89
Industry
Health Technology
CEO
Troy Wilson

Discover more

Frequently Asked Questions

What is Kura Oncology Inc share price today

Can Indians buy Kura Oncology Inc shares?

How can I buy Kura Oncology Inc shares from India?

Can Fractional shares of Kura Oncology Inc be purchased?

What are the documents required to start investing in Kura Oncology Inc stocks?

We are a SEBI registered investement advisor